- Home
- BLTE vs SRPT Comparison
BLTE vs SRPT Comparison
Compare BLTE & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLTE
- SRPT
- Stock Information
- Founded
- BLTE 2018
- SRPT 1980
- Country
- BLTE United States
- SRPT United States
- Employees
- BLTE N/A
- SRPT N/A
- Industry
- BLTE Biotechnology: Pharmaceutical Preparations
- SRPT Biotechnology: Pharmaceutical Preparations
- Sector
- BLTE Health Care
- SRPT Health Care
- Exchange
- BLTE Nasdaq
- SRPT Nasdaq
- Market Cap
- BLTE 2.1B
- SRPT 2.0B
- IPO Year
- BLTE 2022
- SRPT 1997
- Fundamental
- Price
- BLTE $65.74
- SRPT $18.71
- Analyst Decision
- BLTE Strong Buy
- SRPT Hold
- Analyst Count
- BLTE 4
- SRPT 30
- Target Price
- BLTE $96.67
- SRPT $44.37
- AVG Volume (30 Days)
- BLTE 39.8K
- SRPT 9.0M
- Earning Date
- BLTE 08-11-2025
- SRPT 08-06-2025
- Dividend Yield
- BLTE N/A
- SRPT N/A
- EPS Growth
- BLTE N/A
- SRPT N/A
- EPS
- BLTE N/A
- SRPT N/A
- Revenue
- BLTE N/A
- SRPT $2,481,531,000.00
- Revenue This Year
- BLTE N/A
- SRPT $9.41
- Revenue Next Year
- BLTE N/A
- SRPT N/A
- P/E Ratio
- BLTE N/A
- SRPT N/A
- Revenue Growth
- BLTE N/A
- SRPT 64.89
- 52 Week Low
- BLTE $43.70
- SRPT $10.42
- 52 Week High
- BLTE $86.53
- SRPT $138.81
- Technical
- Relative Strength Index (RSI)
- BLTE 52.03
- SRPT 49.39
- Support Level
- BLTE $62.18
- SRPT $17.95
- Resistance Level
- BLTE $66.15
- SRPT $19.61
- Average True Range (ATR)
- BLTE 2.66
- SRPT 1.11
- MACD
- BLTE -0.16
- SRPT -0.04
- Stochastic Oscillator
- BLTE 72.80
- SRPT 25.45
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.
About SRPT Sarepta Therapeutics Inc. (DE)
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.